Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation

ContextWomen with BRCA1 or BRCA2 mutation are often advised to undergo preventive oophorectomy. The effectiveness of this intervention has not been prospectively evaluated in a large cohort.ObjectivesTo estimate the incidence of ovarian, fallopian tube, and primary peritoneal cancer in women who carry a deleterious mutation in BRCA1 or BRCA2. To estimate the reduction in risk of these cancers associated with a bilateral prophylactic salpingo-oophorectomy.Design, Setting, and ParticipantsWomen known to carry a BRCA1 or BRCA2 mutation were identified from an international registry between 1992 and 2003. A total of 1828 carriers at 1 of 32 centers in Canada, the United States, Europe, and Israel completed questionnaires at baseline and follow-up. Participants were observed from the date of study entry until: diagnosis of ovarian, fallopian tube, or peritoneal cancer; death; or the date of the most recent follow-up.InterventionParticipants were divided into women who had undergone bilateral prophylactic oophorectomy and those who had not.Main Outcome MeasureThe incidence of ovarian, peritoneal, and fallopian tube cancer was determined by survival analysis. The risk reduction associated with prophylactic salpingo-oophorectomy was evaluated by a time-dependent survival analysis, adjusting for covariates.ResultsAfter a mean follow-up of 3.5 years, 50 incident ovarian, fallopian tube, and peritoneal cancer cases were reported in the cohort. Of the 1828 women, 555 (30%) underwent a bilateral prophylactic salpingo-oophorectomy prior to study entry, 490 (27%) underwent the procedure after entering the study, and 783 (43%) did not undergo the procedure. There were 32 incident cancers diagnosed in women with intact ovaries (1015/100 000 per year). Eleven cancer cases were identified at the time of prophylactic oophorectomy and 7 were diagnosed following prophylactic oophorectomy (217/100 000 per year). The estimated cumulative incidence of peritoneal cancer is 4.3% at 20 years after oophorectomy. The overall (adjusted) reduction in cancer risk associated with bilateral oophorectomy is 80% (multivariate hazard ratio = 0.20; 95% confidence interval, 0.07-0.58; P = .003).ConclusionOophorectomy is associated with reduced risk of ovarian and fallopian tube cancer in high-risk women, although there is a substantial residual risk for peritoneal cancer in BRCA1 and BRCA2 mutation carriers following prophylactic salpingo-oophorectomy.

[1]  K. Offit,et al.  Prevention and management of hereditary breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[3]  T. Colgan,et al.  Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. , 2002, Gynecologic oncology.

[4]  J. Shepherd Revised FIGO staging for gynaecological cancer , 1989, British journal of obstetrics and gynaecology.

[5]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[6]  Rochelle L. Garcia,et al.  Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. , 2001, Gynecologic oncology.

[7]  T. Colgan,et al.  Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. , 2006, Gynecologic oncology.

[8]  M. King,et al.  Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.

[9]  M. Beattie,et al.  Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  B. Rosen,et al.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. , 2001, American journal of human genetics.

[11]  M. J. van de Vijver,et al.  Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up , 2004, British Journal of Cancer.

[12]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[13]  M. Piver,et al.  Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the gilda radner familial ovarian cancer registry , 1993, Cancer.

[14]  Jacques Ferlay,et al.  Cancer incidence in five continents. , 1976, IARC scientific publications.

[15]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[16]  Chen Kt,et al.  Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. , 1985 .

[17]  J. Tobacman,et al.  INTRA-ABDOMINAL CARCINOMATOSIS AFTER PROPHYLACTIC OOPHORECTOMY IN OVARIAN-CANCER-PRONE FAMILIES , 1982, The Lancet.

[18]  J. Lubiński,et al.  Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status , 2005, Journal of Medical Genetics.

[19]  O. Olopade,et al.  The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. , 2005, Gynecologic oncology.

[20]  T. Rebbeck,et al.  Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Hartge,et al.  Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. , 2003, Journal of the National Cancer Institute.

[22]  R. L. Baldwin,et al.  Cancer incidence in a population of Jewish women at risk of ovarian cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  K. T. Chen,et al.  Peritoneal Carcinomatosis After Prophylactic Oophorectomy in Familial Ovarian Cancer Syndrome , 1985, Obstetrics and gynecology.

[24]  Mark E. Robson,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation , 2002 .